Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/104 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME15973508
PMID: | 15973508
LR: | 20061115
CED: | 20050623
DCO: | 20051205
Autoren: | Kobayashi T; Notoya K; Nakamura A; Akimoto K
Titel: | Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis.
Quelle: | Inflammation research : official journal of the European Histamine Research Society ... [et al.]; VOL: 54 (6); p. 249-55 /200506/
PM: | Print
SU: | IM
Sprache: | English
CY: | Switzerland
JID: | 9508160
ISSN: | 1023-3830
CO: | INREFB
Institution: | Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka, 532-8686, Japan.
DT: | Journal Article
Schlagwörter
CT: | ANIMALS; BODY WEIGHT/drug effects; CARTILAGE/metabolism; CARTILAGE/pathology; CHONDROITIN SULFATES/*therapeutic use; DISEASE MODELS, ANIMAL/*; DISEASE PROGRESSION; FURSULTIAMIN/chemistry; FURSULTIAMIN/*pharmacology; FURSULTIAMIN/therapeutic use; GLUCOSAMINE/*therapeutic use; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 1/metabolism; OSTEOARTHRITIS/*drug therapy; OSTEOARTHRITIS/pathology; PROTECTIVE AGENTS/chemistry; PROTECTIVE AGENTS/pharmacology; PROTECTIVE AGENTS/therapeutic use; RABBITS; TIBIA/metabolism; TIBIA/pathology
CTG: | TIER; KÖRPERGEWICHT/Arzneimittelwirkungen; KNORPEL/Stoffwechsel; KNORPEL/Pathologie; CHONDROITINSULFATE/*therapeutische Anwendung; KRANKHEITSMODELLE, TIER/*; KRANKHEITSPROGRESSION; FURSULTIAMIN/Chemie; FURSULTIAMIN/*Pharmakologie; FURSULTIAMIN/therapeutische Anwendung; GLUCOSAMIN/*therapeutische Anwendung; IMMUNHISTOCHEMIE; MÄNNLICH; INTERSTITIELLE KOLLAGENASE/Stoffwechsel; OSTEOARTHROSE/*Arzneimitteltherapie; OSTEOARTHROSE/Pathologie; SCHUTZSTOFFE/Chemie; SCHUTZSTOFFE/Pharmakologie; SCHUTZSTOFFE/therapeutische Anwendung; KANINCHEN; TIBIA/Stoffwechsel; TIBIA/Pathologie
TE: | Protective Agents; Glucosamine/3416-24-8; Fursultiamin/804-30-8; Chondroitin Sulfates/9007-28-7; Matrix Metalloproteinase 1/E.C. 3.4.24.7
CR: | 3416-24-8; 804-30-8; 9007-28-7; E.C. 3.4.24.7
AB: | OBJECT AND DESIGN: The therapeutic effect of glucosamine hydrochloride (GH) and chondroitin sulfate (CS) in combination with fursultiamine, a vitamin B1 derivative, on the development of cartilage lesions was investigated in an animal model of osteoarthritis (OA). METHODS: The OA model was created by partial medial meniscectomy of the right knee joint (day 0). The rabbits were placed into three experimental groups: operated (OA) rabbits that received placebo treatment, OA rabbits that received GH (1000 mg/kg) + CS (800 mg/kg), and OA rabbits that received GH + CS + fursultiamine (100 mg/kg). Each treatment was initiated on day 3 and continued for 8 weeks. Macroscopic and histologic analyses were performed on the cartilage. The level of MMP-1 in OA cartilage chondrocytes was evaluated by immunohistochemistry. RESULTS: Only the group receiving combined treatment with GH + CS + fursultiamine showed a significant reduction in the severity of macroscopic and histologic lesions on tibial plateau, which is the weight bearing cartilage surface of the tibia, compared with placebo-treated OA rabbits. This treatment group also revealed a small, but significant, decrease in the body weight gain of the rabbits. In cartilage from placebo-treated OA rabbits, a significantly higher percentage of chondrocytes in superficial layer stained positive for MMP-1 compared with unoperated control. Rabbits treated with the GH + CS + fursultiamine revealed a significant reduction in the level of MMP-1. CONCLUSION: These results suggest that the chondroprotective effect of GH + CS is enhanced by the addition of fursultiamine in experimental OA. This effect was associated with a reduction in the level of MMP-1, which are known to play an important role in the pathophysiology of OA lesions.

» Volltext »
» Fenster schließen »